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1. Introduction
The chemotherapy of infections caused by bacteria that inhabit intracellularly presents a
number of uncommon challenges. Many bacteria have found the way to produce a “silent”
infection inside the cells and to avoid from their bactericidal mechanisms. However many
methods for diagnosing and treating these and other bacterial infections presently exist, there
is an essential need for new and improved approaches for bacterial destruction. Although the
therapeutic efficacy of drugs has been well recognized, inefficient delivery could result in
insufficient therapeutic index. It is now clear that a nanotechnology-driven approach using
nanoparticles to selectively target and destroy pathogenic bacteria can be successfully
implemented. Nanotechnology is one approach to overcome challenges of conventional drug
delivery systems based on the development and fabrication of nanostructures. Some chal‐
lenges associated with the technology are as it relates to drug effectiveness, toxicity, stability,
pharmacokinetics and drug regulatory control. Localized diseases such as infection and
inflammation not only have perforated vasculature but also overexpress some epitopes or
receptors that can be used as targets. Thus, nanomedicines can also be actively targeted to these
locations. Various types of nanoparticulate systems have been tried as potential drug delivery
systems, containing biodegradable polymeric nanoparticles, polymeric micelles, nanocap‐
sules, nanogels, fullerenes, solid lipid nanoparticles (SLN), nanoliposomes, dendrimers, metal
nanoparticles and quantum dots. Nanoparticles have been found useful in the development
of systemic, oral, pulmonary, transdermal and other administration routes to study drug
targeting, the enhancement of drug bioavailability and protection of drug bioactivity and
stability. In recent years, encapsulation of antimicrobial drugs in nanoparticle systems has
emerged as an innovative and promising alternative that enhances therapeutic effectiveness
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and minimizes the undesirable side effects of drugs. The major goals in designing nanoparti‐
cles as delivery systems are to control particle size, surface properties and release of pharma‐
cologically active agents in order to achieve the site-specific action at the therapeutically
optimal rate and dose regimen. This chapter focuses on nanoparticle-based drug delivery
systems and clinical applications to treat a variety of bacterial infectious diseases and their
potential applications in the field of medicine and biology.
2. Types of infections
Infectious disease is a clinically obvious disorder resulting from the presence of a pathogenic
agent which can either be a virus, bacterium, fungus or parasite. These diseases are also called
communicable diseases due to their ability to get transferred from one person to another
(malaria, tuberculosis) and also sometimes from one species to another (flu, influenza).
Infectious diseases can be vastly classified as: 1) known diseases which are insistently there
(e.g., dengue, malaria, tuberculosis); 2) new, previously unknown diseases (e.g., severe acute
respiratory syndrome); and 3) diseases which threaten to enhance in the near future (e.g., avian
influenza). These diseases own a great risk as more than half of the deaths happening world‐
wide can be attributed to these diseases, particularly in developing countries [1]. Parasitism is
based on the benefits acquired by a pathogenic bacterium invading the host and causing an
infection. A bacterial infection is the process occurring when the microbe manifests its
pathogenicity, and thus its capacity of inducing disease, by invading and causing a damage
(locally or systemically) of the host organism. Consequently, the infectious disease could result
in an acute infection, with a short and severe course, or a chronic, low-grade and long lasting
infection [2].
3. Classification of bacterial pathogens
The classification of infectious agents inregards to their infective lifestyles in the host and
corresponding pathogenic indications must be precisely described [3]. In the life of a microbe,
the intracellularity and extracellularity are unclear designations unless obviously related to
the situation where it is living. For a microbial pathogen, what matters is whether intra-or
extracellularity is in the basis of the in vivo life and in relationship with pathogenicity.
Classically, infectious agents are indicated as extracellular and intracellular pathogens [4-6].
3.1. Extracellular pathogens
Staphylococcus aureus, Streptococcus pyogenes, Pseudomonas aeruginosa, Escherichia coli are typical
examples of bacteria which have been considered extracellular pathogens, and lesion infec‐
tions, osteomyelitis, scarlet fever, specified forms of pneumonia, urinary tract infections are
examples of infections caused by these pathogens [7]. To produce disease, extracellular
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pathogens utilize any portal of entry provided a satisfactory fluid medium be recognized at
the site of lesion [4]. Extracellular pathogens utilize virulence mechanisms to avoid the
antimicrobial capabilities of humoral immunity and phagocytosis thus advancing extracellular
reproduction [8], in contrast with intracellular pathogens that promote the entry in to host cells
containing macrophages and non-professional phagocytes such as epithelial cells [9].
3.2. Intracellular pathogens
Classical examples of intracellular pathogens are Brucella abortus, Listeria monocytogenes,
Mycobacterium tuberculosis, Salmonella enterica, and typical infectious diseases caused by them
include brucellosis, listeriosis, tuberculosis, and salmonellosis [10]. Intracellular pathogenic
bacteria have the ability to establish a relationship in the sensitive host which includes a stage
of intracellular reproduction [11]. To establish an infection, these pathogens have to make
contact with the appropriated type of host cell that provides suitable intracellular conditions
for growth [4]. Bacteria such as Mycobacterium, Legionella, Brucella or Listeria have extended the
ability to resist and replicate inside various mammalian cells including the aggressive
phagocytic cells, which establish the first-line defense against invading pathogens [12].
4. Targeted therapy of infections using nanoparticles
The hydrophilic nature of some antibiotics prevents thier capacity to penetrate the cells and,
furthermore, the internalized molecules are mostly accumulated in lysosomes, where the
bioactivity of the drug is low. Therefore, limited intracellular activity against sensitive bacteria
is often found [13, 14]. Thus, the use of drug delivery systems (DDS) has been suggested for
passive targeting of infected cells of the mononuclear phagocytic system to enhance the
therapeutic index of antimicrobials in the intracellular environment, while minimizing the side
effects associated with the systemic administration of the antibiotic [15]. The pathophysiolog‐
ical and anatomical changes of the affected tissues in a disease state offer many possibilities
for the delivery of various nanotechnology-based products [16]. Bacteria gains antibiotic
resistance due to three reasons namely: 1) modification of active site of the target resulting in
reduction in the efficiency of binding of the drug, 2) direct destruction or modification of the
antibiotic by enzymes produced by the organism or, 3) efflux of antibiotic from the cell [17].
Nanoparticles (NPs) can target antimicrobial agents to the site of infection, so that higher doses
of drug can be given at the infected site, thereby overcoming existing resistance mechanisms
with fewer harmful effects upon the patient [18]. As with nanoparticles targeting intracellular
bacteria, nanoparticles targeting the site of infection can release high concentrations of
antimicrobial drugs at the site of infection, while keeping the total dose of drug administered
low. Nanoparticles can be targeted to sites of infection passively or actively. Passively targeted
nanoparticles selectively undergo extravasation at sites of infection, where inflammation has
led to enhanced blood vessel porousness. Actively targeted nanoparticles contain ligands (e.g.
antibodies) that bind receptors (e.g. antigens) at sites of infection [19]. Passive targeting with
nanoparticles, however, faces multiple barriers on the way to their target; these include
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mucosal barriers, nonspecific uptake of the particle and non-specific delivery of the drug (as
a result of uncontrolled release) [20]. Passive nanoparticulate targeting of chemotherapeutics
to the cells and organs of the reticuloendothelial system (RES) has been a significant area of
research for the treatment of chronic infectious diseases. The RES comprises monocyte-lineage
immune cells such as macrophages and dendritic cells, as well as the spleen, liver, and kidneys.
These components of the RES are consistently implicated as sites of nanoparticle clearance and
localization [21]. The few studies that have compared targeted and nontargeted systems have
demonstrated that the role of targeting ligands in localization at the target site is application
dependent. Targeted delivery to atherosclerotic lesions is greatly enhanced by targeting
ligands which impart an improved ability to accumulate at the target site [22]. Many active
targeting strategies use the enhanced permeability and retention (EPR) effect, so that active
and passive targeting mechanisms act synergistically that lead to higher concentration of
nanostructures in the infected region than that in healthy tissues [23]. Targeted antimicrobial
drug delivery to the site of infection, particularly intracellular infections, using NPs is a
sensational prevision in treating infectious diseases [24, 25]. Intracellular microorganisms are
taken up by alveolar macrophages (AMs), intracellulary survive or reproduce, and are
persistent to the antimicrobial agents. Antibiotics loaded NPs can enter host cells through
endocytosis, followed by releasing the payloads to delete intracellular microbes [26, 27]. The
need to target drugs to specific sites is increasing day by day as a result of therapeutic and
economic factors. Nanoparticulate systems have shown enormous potential in targeted drug
delivery, specially to the brain [28].
5. Challenges in treating infectious diseases using nanotechnology
Use of antibiotics began with commercial production of penicillin in the late 1940s and claimed
to be a great success until the 1970–1980s when newer and even stronger antibiotics were
additionally improved [29]. Resistance to antimicrobial drugs becomes a threatening problem
not only in hospitals but also in communities, resulting in fewer effective drugs available to
control infections by “old” well-known bacteria [30]. Carrier systems allow antibiotics to be
delivered selectively to phagocytic cells and to increase their cellular penetration in order to
treat intracellular infections, particularly in the case of antibiotics active against microorgan‐
isms that produce this type of infection but that have a low intracellular penetration capacity
[31]. Nevertheless, significant challenges remain for implementation of clinically viable
therapies in this field. New challenges in the development of nanotechnology-based drug
delivery systems include: the possibility of scale-up processes that bring innovative therapeu‐
tic techniques to the market rapidly, and the possibility of obtaining multifunctional systems
to carry out several biological and therapeutic requirements [32]. Thus, a drug delivery system
should be multifunctional and possess the ability to switch on and switch off specified
functions when urgent. Another important requirement is that different properties of the
multifunctional drug delivery systems are harmonized in an optimal fashion [33]. Therefore,
design, discovery, and delivery of antimicrobial drugs with improved efficacy and avoidance
of resistance are extremely requested [34].
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5.1. Advantages of nanoantibiotics
The use of NPs as delivery vehicles for antimicrobial agents suggests a new and promising
model in the design of effective therapeutics against many pathogenic bacteria [35]. Antimi‐
crobial NPs propose several clinical advantages. First, the surface properties of nanoparticles
can be changed for targeted drug delivery for e.g. small molecules, proteins, peptides, and
nucleic acids loaded nanoparticles are not known by immune system and efficiently targeted
to special tissue types [36]. Second, nanocarriers may overcome solubility or stability issues of
the drug and minimize drug-induced side effects [37]. Third, using nanotechnology, it may be
possible to achieve co-delivery of two or more drugs or therapeutic modality for combination
therapy [33]. Fourth, NP-based antimicrobial drug delivery is promising in overcoming
resistance to common antibiotics developed by many pathogenic bacteria [38]. Five, adminis‐
tration of antimicrobial agents using NPs can progress therapeutic index, extend drug
circulation (i.e., extended half-life), and achieve controlled drug release, increasing the overall
pharmacokinetics [30]. Six, the system can be used for several routes of administration
including oral, nasal, parenteral, intra-ocular etc [39]. Thus, antimicrobial NPs are of great
interest as they provide a number of benefits over free antimicrobial agents [35].
5.2. Disadvantages of nanoantibiotics including nanotoxicology
Although nanoantibiotics promises significant benefits and advances in addressing the key
obstacles in treating infectious diseases, there are foreseeable challenges in translating this
exciting technology for clinical application [40]. Profound knowledge about the potential
toxicity of nanoantibiotics is also needed to guarantee successful clinical translation [41]. The
toxic effects of antimicrobial NPs on central nervous system (CNS) are still unknown, and the
interactions of NPs with the cells and tissues in CNS are poorly understood [42]. Furthermore,
NPs represent size-specific properties that limit the use of currently available in vitro experi‐
ments in a general way, and there is no standardized definition for NP dose in mass, number,
surface area, and biological samples (e.g., blood, urine, and inside organs) [43, 44]. This means
that there is a high request to develop new characterization techniques that are not affected by
NP properties as well as biological media [45]. NPs usually have short circulation half-life due
to natural defense mechanism of human body for eliminating them after opsonization by the
mononuclear phagocytic system. Therefore, the particles surfaces need to be changed to be
hidden to opsonization [46]. A hydrophilic polymer such as polyethylene glycol is prevalently
utilize for this purpose because it has worthwhile characteristics such as low degree of
immunogenicity and antigenicity, chemical inertness of the polymer backbone, and availabil‐
ity of the terminal primary hydroxyl groups for derivatization [47].
6. Nanotechnology-based drug delivery systems
Perfectly, nanoparticulate drug delivery system should selectively accumulate in the necessary
organ or tissue and at the same time, penetrate target cells to deliver the bioactive agent [48].
It has been proposed that, organ or tissue accumulation could be achieved by the passive or
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antibody-mediated active targeting, while the intracellular delivery could be mediated by
specified ligands or by cell-penetrating peptides [49-53]. The purpose of drug delivery is to
carry out sustained (or slow) and/or controlled drug release and therefore to improve efficacy,
safety, and/or patient comfort [54]. Thus, the use of drug delivery systems has been suggested
for passive targeting of infected cells of the mononuclear phagocytic system to enhance the
therapeutic index of antimicrobials in the intracellular environment, while minimizing the side
effects related with the systemic administration of the antibiotic [55]. These systems propose
many advantages in drug delivery, mainly focusing on improved safety and efficacy of the
drugs, e.g. providing targeted delivery of drugs, improving bioavailability, extending drug or
gene effect in target tissue, and improving the stability of therapeutic agents against chemical/
enzymatic degradation [56]. The nanoscale size of these delivery systems is the basis for all
these advantages [57]. It is therefore assumed that, DDS with enhanced targeting property is
highly promising in increasing the efficiency and efficacy of therapy while at the same time
minimizing side effects [33].
7. Types of drug carriers in medicine
7.1. Polymeric nanoparticles
Polymer-based nanoparticles are submicron-sized polymeric colloidal particles in which a
therapeutic agent of interest can be embedded or encapsulated within their polymeric matrix
or adsorbed or conjugated onto the surface [59]. The drugs may also be sensitive to gastroin‐
testinal degradation by digestive enzymes. The advantage of using polymeric nanoparticles
is to permit encapsulation of bioactive molecules and protect them against enzymatic and
hydrolytic degradation [60]. Therapeutically used polymeric nanoparticles are composed of
biodegradable or biocompatible materials, such as poly (ε-caprolactone) (PCL), poly(lactic
acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), alginic acid, gelatin and chitosan [61-64].
Polymeric nanocarriers (NCs) may suggest an opportunity to target chlamydial organism
within the contents, as NCs have been shown to be excellent intracellular carriers, and can be
appropriate to encapsulate a variety of therapeutics containing biomacromolecules. Compared
to free drugs, polymeric NCs have many other advantages including improved drug bioa‐
vailability, high carrier capacity, the ability to release the payload in a controlled behavior and
to adapt to different routes of administration and to concentrate in inflammatory and infectious
locations by virtue of their enhanced permeability and preservation. Conjugating NCs with
specific moieties have also been shown to enhance their targeting to specific cells and tissues
[65]. Polymeric nanoparticles have been extensively explored as means for drug solubilization,
stabilization and targeting [66]. Polymeric nanoparticles possess several unique characteristics
for antimicrobial drug delivery. Firstly, polymeric nanoparticles are structurally stable and
can be synthesized with a sharper size distribution. Secondly, particle properties such as size,
zeta potentials, and drug release profiles can be accurately tuned by selecting different polymer
lengths, surfactants, and organic solvents during the synthesis. Thirdly, the surface of poly‐
meric nanoparticles typically contains functional groups that can be chemically changed with
either drug moieties or targeting ligands [67]. For targeted antimicrobial delivery, polymeric
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nanoparticles have been repeatedly ornamented with lectin, which is a protein that binds to
simple or complex carbohydrates present on most bacterial cell walls. For example, lectin-
conjugated gliadin nanoparticles were studied for treating Helicobacter pylori related infection
diseases. It has been found that lectin-conjugated nanoparticles bind specially to carbohydrate
receptors on cell walls of H. pylori and release antimicrobial agents into the bacteria [30, 67].
Rifampicin-loaded polybutylcyanoacrylate nanoparticles have also shown enhanced antibac‐
terial activity both in vitro and in vivo against S. aureus and Mycobacterium avium due to an
effective delivery of drugs to macrophages [68].
7.2. Hydrogels
A hydrogel is a network of hydrophilic polymers that can swell in water and hold a large
amount of water while maintaining the structure [69]. Drugs can be loaded into the polymer
matrix of these materials and controlled release is dependent on the diffusion coefficient of the
drug across the hydrogel network [70]. Amongst the several types of drug delivery systems
that have been developed in order to improve effectiveness and biocompatibility, hydrogels
are extremely promising. Hydrogels are biocompatible hydrophilic networks that can be
constructed from both synthetic and natural materials [71]. In an overall view, hydrogels can
be classified based on a variety of characteristics, containing the nature of side groups (neutral
or ionic), mechanical and structural features (affine or phantom), method of preparation
(homo-or co-polymer), physical structure (amorphous, semicrystalline, hydrogen bonded,
supermolecular, and hydrocollodial), and responsiveness to physiologic environment stimuli
(pH, ionic strength, temperature, electromagnetic radiation, etc.) [72-75]. Classically, hydro‐
gels have been used to deliver hydrophilic, small-molecule drugs which have high solubilities
in both the hydrophilic hydrogel matrix and the aqueous solvent swelling the hydrogel [76].
Hydrogel-based hydrophobic drug delivery is in many respects a more difficult problem given
the innate incongruity of the hydrophilic hydrogel network and the hydrophobic drug. A
variety of strategies for introducing hydrophobic domains directly into otherwise hydrophilic
hydrogel networks have permitted significant improvements in the loading of hydrophobic
drugs [76]. Hydrogel/glass composite (Nitric oxide-releasing nanoparticles) NO NPs have also
been shown to have a high degree of effectiveness against (Methicillin-resistant Staphylococcus
aureus) MRSA infection in several different mouse models. In one mouse study by Martinez
et al., administration of topical hydrogel/glass composite NO NPs into skin wounds infected
with MRSA reduced bacterial burden significantly compared to controls [77]. Despite these
many advantageous properties, hydrogels also have several limitations. The low elastic force
of many hydrogels limits their use in load-bearing applications and can result in the precocious
decomposition or flow away of the hydrogel from a targeted local site. This limitation may not
be important in many typical drug delivery applications (e.g. subcutaneous injection) [78].
7.3. Metal nanoparticles
Metal-based nanoparticles of different shapes, sizes (between 10 to 100 nm) have also been
investigated as diagnostic and drug delivery systems. Most common metallic nanoparticles
contain gold, nickel, silver, iron oxide, zinc oxide, gadolinium, and titanium dioxide particles
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[79]. Metal nanoparticles, which have a high specific surface area and a high fraction of surface
atoms, have been studied extensively because of their unique physicochemical characteristics
including catalytic activity, optical properties, electronic properties, antimicrobial activity, and
magnetic properties [80-82]. Even though metallic nanoparticles are biocompatible and
immobile carriers, a significant fraction of metal particles can be retained and accumulated in
the body after drug administration, probably causing toxicity. Consequently, the use of
metallic nanoparticles for drug delivery is a concern [83].
7.3.1. Gold nanoparticles
Gold nanoparticles (GNPs) have found many applications in many fields such as cancer
diagnosis and therapy, drug and gene delivery, DNA and ptotein determination, etc. Due to
their unique properties of small size, large surface area to volume ratio, high reactivity to the
living cells, stability over high temperatures and translocation into the cells [84]. GNPs are
suitable for the delivery of drugs to cellular destinations due to their ease of synthesis,
functionalization and biocompatibility. GNPs functionalized with targeted specific biomole‐
cules can effectively destroy cancer cells or bacteria [85]. The efficacy of GNPs conjugated to
several antibiotics has also been the subject of some studies by Grace and Saha et al. They
discovered that GNPs conjugates were more efficient in inhibiting the growth of Gram-positive
and Gram-negative bacteria in comparison with the same dosage of antibiotics utilized alone.
Their results suggest that GNPs can act as an effective drug carrier in a drug delivery system
[86, 87]. Conjugates of gold nanoparticles with antibiotics and antibodies also have been used
for selective photothermal killing of protozoa and bacteria [88]. Gu et al. synthesized stable
gold nanoparticles covered with vancomycin and showed significant enhancement of anti‐
bacterial activity, in comparison with the activity of the free antibiotic [89]. In another report,
Selvaraj et al. utilized the anticancer compound 5-fluorouracil bound to GNPs and found that
the resulting conjugate was significantly more effective against a range of bacterial and fungal
organisms in comparison with alone [90]. Recently, it has been reported that the gentamicin
conjugated with gold nanospheres was significantly more effective against S. aureus in
comparsion with free gentamicin [91]. Each GNP surrounded by a number of drug moieties
acts as a single group against the microbial organisms [92]. The greater antibacterial effect of
the GNPs conjugates has been ascribed to their ability to bind to and/or penetrate the cell wall
and, in doing so they are able to deliver a large number of antibiotic molecules into a highly
localized volume [93].
7.3.2. Silver nanoparticles
Silver nanoparticles of size smaller than 100 nm contain about 10000–15000 silver atoms [94,
95]. They are prepared by engineering the metallic silver into ultrafine particles by numerous
physical methods, which include spark discharging, electrochemical reduction, solution
irradiation and cryochemical synthesis [96]. The most widely used and known application of
silver nanoparticles is in the medical sciences. These include topical ointments and creams
containing silver to prevent infection of burns and open wounds [97]. Among the many
different types of metallic and metal oxide NPs, silver nanoparticles have demonstrated to be
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the most effective against bacteria, viruses, and other eukaryotic microorganisms [98, 99].
Antibacterial properties inhibit the reproduction of bacteria, which is a microbe. The silver
nanoparticles can “inactivate proteins, blocking respiration and electron transfer, and subse‐
quently inactivating the bacteria” [100]. The antibacterial properties of the silver nanoparticles
depend on the size of the particles; the smaller the particles the better the effect. The particle
size is a major factor because the smaller the particle the greater the surface area, which allows
for greater interaction with the bacteria [100]. It has been reported that combined use of silver
nanoparticles with antibiotics, such as penicillin G, amoxicillin, erythromycin, and vancomy‐
cin, resulted in enhanced and synergistic antimicrobial effects against Gram-positive and
Gram-negative bacteria (e.g., E. coli and S. aureus) [80, 101, 102]. Although beneficial as
antimicrobial agents, silver nanoparticles have adverse effects on cells such as the production
of reactive oxygen species which are toxic to both bacteria and eukaryotic cells [103, 104]. In
contrast, the cytotoxicity of gold nanoparticles is quite low, and they have been used for
medical imaging and have served as scaffolds for drug delivery [105, 106].
7.3.3. Magnetic nanoparticles
Magnetic nanoparticles engineered as drug delivery devices retain the ability to track their
movement through the body. This is significant because it allows clinicians to monitor the
effectivity of injected therapeutics to reach their target sites [107]. Iron oxide nanoparticles
(IONPs) are magnetic Fe3O4 or Fe2O3 nanocrystals which can interact with external magnetic
fields, offering different opportunities in nanomedicine, e.g., as contrast agents in MRI, for
magnetic hyperthermal therapies, or as magnetically triggerable drug delivery systems [108].
There are some studies on evaluating the toxicity of magnetite nanoparticles on eukaryote
cells, which their results showed negligible toxicity in eukaryote cells of the modified mag‐
netite nanoparticles with different surfactants such as glycine or oleic acid. But the toxicity of
magnetite nanoparticles on bacteria cells has not been reported [109]. However, in most of the
cases where magnetic nanocarriers have been used, difficulties in achieving these objectives
appeared. In turn, magnetic force may not be strong enough to overcome the force of blood
flow and to accumulate magnetic drugs only at target site [110]. Therefore, designing magnetic
drug delivery systems requires taking into consideration many factors, e.g., magnetic prop‐
erties and size of particles, strength of magnetic field, drug loading capacity, the place of
accessibility of target tissue, or the rate of blood flow [111]. The vancomycin functionalized
magnetic nanoparticles for pathogen detection have been investigated by Gu et al. [112].
Vancomycin can be attached to the magnetic nanoparticles surface by activating the–COOH
group of vancomycin followed by reaction with the amine groups on the surface of the iron
oxide nanoparticles. The vancomycin conjugated iron oxide nanoparticles were utilized as
probes to selectively entrap S. saprophyticus (a pathogen that usually infects the urinary tract
of young women) and S. aureus bacteria from urine specimen using a magnetic field [1, 112].
It has been reported that the various nanoparticles, Al2O3, Fe3O4, CeO2, ZrO2 and MgO were
subjected to evaluate its antibacterial potential against ophthalmic pathogens such as Pseudo‐
monas aeruginosa, Acinetobacter sp., Klebsiella pneumoniae, E. coli, Streptococcus viridans and
Streptococcus pyogenes. Among the nanoparticles, Fe3O4 showed maximum activity against
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Pseudomonas aeruginosa. The reactive oxygen species (ROS) generated by Fe3O4 nanoparticles
could kill bacteria without harming nonbacterial cells [113].
7.4. Silica nanoparticles
Silica materials are suitable for several important biological applications, such as drug delivery,
imaging, oxygen carrier or controlled release [114]. Silica materials have been proved to be
efficient carriers for the local release of antibiotics, which could be of interest in the context of
biofilm associated infections, which are a real challenge for the modern medicine [115].
Moreover, mesoporous silica has been found to be relatively “non-toxic” and biocompatible,
however of course depending on dose and administration route [116]. Nanoporous silica
materials possess large pore volumes and high surface areas, allowing the absorption of large
amounts of drugs, thus providing sufficient concentrations for local treatment. The surface of
silica materials is reactive due to the presence of silanol groups. This allows for facile modifi‐
cation by silanization reactions and thus opens possibilities for enhancing the drug loading
and for controlling the drug release [117]. Till present there are only few reports concerning
the application of silica materials, crystalline or amorphous, in the antimicrobial therapy [115].
Zhang et al. suggested a highly-sensitive fluoroimmunoassay for the determination of
staphylococcal enterotoxin C1 (SEC1). This method utilizes anti-SEC1 coated NPs for detection
which is possible in food samples and enables fluorescence microscopy imaging for the
determination of SEC1 [118]. Recently, Grumezescu et al. reported that silica nanostructures
have significantly improved the anti-staphylococcal activity of bacitracin and kanamycin
sulfate, as revealed by the drastic decrease of the minimal inhibitory activity of the respective
antibiotics loaded in the SiO2 nanopowder. These results, correlated with the high biocom‐
patibility of the porous silica structure recommend it as an efficient vehicle for the local delivery
of antibiotics in lower active doses, reducing thus their cytotoxicity and side effects [119].
7.5. Micelles
Micelles are submicroscopic aggregates of surfactant molecules assembly of amphiphillic
block copolymers or polymer-lipid conjugates or other surface-active molecules that self-
assemble in aqueous media to form structures with a hydrophobic core [120, 121]. The ability
to functionalise the micelles as well as tailor the disintegration behaviour by varying the co-
polymer composition are beneficial parameters in making them drug carriers of choice. Their
small size (1-50 nm) makes them ideal for intravenous delivery. In addition they are also more
stable, when compared to liposomes due to be ability to design them to be chemically stable
and biocompatible [122]. One specific feature of micelles is that the amount of drug released
can be controlled by an external stimulus like pH, temperature, ultrasound or certain enzymes
[123]. Other unique properties of polymeric micelles are that they are easily altered with small
functional groups that enhance their targeting potential [124]. Generally, polymeric surfactants
are known to be less toxic than low-molecular-weight surfactants, such as sodium dodecyl
sulfate. Furthermore, in theory, polymeric micelles are considered very safe in relation to
chronic toxicity [125]. The disadvantage for the polymeric micelle systems is the immature
technology for drug incorporation in a physical manner. The another disadvantage is much
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slower extravazation of polymeric carrier systems than that of low molecular weight drugs.
This results from a difference in extravazation mechanisms between polymeric carrier systems
and low molecular weight drugs [126].
7.6. Liposomes
Liposomes are small spherical vesicles in which one or more aqueous parts are completely
surrounded by molecules that have hydrophilic and hydrophobic functionality. Liposomes
change with composition, size, surface charge and method of preparation. They can be single
or in multiple bilayers. Those including one bilayer membrane are called small unilamellar
vesicles or large unilamellar vesicles based on their sizes [127]. Nanoparticulate DDS, such as
liposomes, are mostly used to enhance the efficacy of drug and DNA delivery and targeting
[128, 129]. Liposomes are also the most broadly used antimicrobial drug delivery vehicles
because their lipid bilayer structure imitators the cell membrane and can readily fuse with
infectious microbes [30]. One of the disadvantages of liposomal antibiotics is the short shelf-
lives of lipid vesicles, which limits drug stability. Short shelflives can be conditioned by both
physical and chemical processes [130]. There are many advantages of liposomes as antibiotic
carriers: improved pharmacokinetics and biodistribution; decreased toxicity; enhanced
activity against intracellular pathogens; target selectivity; enhanced activity against extracel‐
lular pathogens, in particular to overcome bacterial drug resistance [131]. The ability of
liposomes to alter drug distribution depends mostly on their size and surface properties [132].
Thus, liposomal encapsulation of antibiotics helps to increase their therapeutic index with
mode of action related to increasing the drug concentration at the site of infection and/or
reducing its toxicity [133]. For instance, encapsulation of vancomycin and teicoplanin in
liposomes resulted in significantly improved elimination of intracellular methicillin resistant
S. aureus (MRSA) infection [35]. Netilmicin liposomes showed an increase in pharmacological
activity in a peritonitis model of mice infected with E. coli, in terms of survival both prophy‐
lactically and therapeutically [134]. Recently, Deol and Khuller produced lung-specific
liposomes made of phosphatidylcholine, cholesterol, dicetylphosphate, O-steroyl amylopectin
and monosialogangliosides/distearylphosphatidylethanolamine-poly (ethylene glycol) 2000
for the targeted delivery of anti-Tuberculosis (TB) drugs to the lung [135].
7.7. Solid lipid nanoparticles (SLN)
Solid lipid nanoparticles (SLN) were developed at  the beginning of 1990s as an alterna‐
tive carrier system to emulsions, liposomes and polymeric nanoparticles as a colloidal carrier
system for controlled drug delivery [20]. SLNs are sub-micron colloidal carriers, ranging
from 50 nm to 1 μm, that are composed of physiological  lipid dispersed in water or in
aqueous surfactant solution [136]. In the last decade SLNs have gained considerable interest
as  novel  particulate  drug  delivery  systems.  SLNs  are  suitable  for  the  incorporation  of
lipophilic and hydrophilic drugs within the lipid matrix in considerable amounts [137]. SLN
consist of a solid lipid matrix at room and body temperature, where the drug is normally
incorporated in the submicron size range (below 1 µm) [35]. Some advantages of SLNs are
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possibility  of  controlling drug release  and drug targeting,  increased drug stability,  high
drug payload, possibility of the incorporation of lipophilic and hydrophilic drugs, lack of
biotoxicity of the carrier, no problems with respect to large-scale production, sterilization
possibility,  and good tolerability [138].  Common disadvantages of SLN are their particle
growing,  their  unpredictable  gelation  tendency,  their  unexpected dynamics  of  polymor‐
phic transitions and their inherent low incorporation rate due to the crystalline structure
of the solid lipid [139]. SLNs are considered good drug carriers to obtain sustained release
of antibiotics [140]. SLNs can act as promising carriers for sustained ciprofloxacin release
in infections or to enhance the bioavailability of tobramycin from antibiotic-loaded SLN in
the aqueous humor for topical ocular delivery [141, 142]. Nimje et al. (2009) reported the
selective delivery of rifabutin, another antituberculosis drug, to alveolar tissues, using drug-
loaded solid lipid nanoparticles, increasing the therapeutic margin of safety and reducing
side effects [143]. Another prominent example of SLNs-based drug delivery is pulmonary
delivery of antimicrobials to treat tuberculosis, a serious lung infection caused by Mycobac‐
terium tuberculosis. In some severe cases, tuberculosis infection spreads from the lungs and
affects the lymphatic systems. SLNs can facilitate the delivery of anti-tuberculosis drugs
such  as  rifampin,  isoniazidand  pyrazinamide  to  the  lungs  as  well  as  to  the  lymphatic
systems  [144].  Even  though  the  development  history  of  SLN-based  antimicrobial  drug
delivery systems is  relatively shorter than other nanoparticle systems such as liposomes
and polymeric nanoparticles, SLNs have shown great therapeutic potentials [145].
7.8. Fullerenes
Fullerenes are a new form of carbon, other forms being diamond, graphite, and coal. They can
take three forms of a hollow sphere, ellipsoid, or tube. Their small size, spherical shape, and
hollow interior all provide therapeutic opportunities [146]. The most abundant form of
fullerenes is buckminsterfullerene (C60) with 60 carbon atoms arranged in a spherical structure
[147]. The shape of the molecule, recognized as truncated icosahedron, resembles that of a
football ball, containing 12 pentagons and 20 hexagons, in which every carbon atom forms
bond to three other neighbor atoms through sp2 hybridization [148]. Friedman et al and
Schinazi et al distinguished that the hydrophobic cleft of the human immunodeficiency virus
(HIV)-1 protease can seamlessly host a C60 molecule [149]. This discovery was the first piece
of evidence that fullerenes could have pharmaceutical significance through interactions with
biological targets, highlighting the great potential of fullerenes in medicinal applications. Since
fullerenes possess unique geometrical shapes, as well as novel photophysical properties, in
addition to being efficient radical scavengers, a wide variety of biological applications have
been considered [150-152]. Some studies asserted that C60 could be also utilized for the
photodynamic inactivation of bacteria, as persuasively demonstrated in studies examining the
effects of water-soluble and nanoparticulate C60 on various bacterial strains [153]. The effects
were significantly more pronounced in Gram positive (Staphylococcus spp., Streptococcus spp.)
than in Gram negative bacteria (Klebsiella Pneumoniae, Escherichia coli, Pseudomonas aeruginosa,
Salmonella typhi, Streptococcus pyogenes), indicating that the bactericidal action was dependent
on the fullerene insertion into the microbial cellwall, the structure of which differs between
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Gram positive and Gram negative bacteria [154]. Additionally, the quinazolin–fullerene
conjugate 18 was reported to have an inhibitory potential of 98.83% at a minimal inhibitory
concentration of 1.562 μg/mL when treating M. tuberculosis [155].
7.9. Dendrimers
First discovered in the early 1980’s by Tomalia and co-workers, such hyperbranched molecules
were called dendrimers [156]. Dendrimers are globular repeatedly branched macromolecules
that exhibit controlled patterns of branching with multiple arms extending from a central core
[157]. The well defined structure, monodispersity of size, surface functionalization capability,
and stability are properties of dendrimers that make them attractive drug carrier candidates
[20]. Asymmetric dendrimers are synthesized by coupling dendrons of different generations
(G1-G4) to a linear core, which yields a branched dendrimer with a nonuniform orthogonal
architecture. This asymmetry allows for tunable structures and molecular weights, with
precise control over the number of functional groups available on each dendron for attachment
of drugs, imaging agents, and other therapeutic moieties [158]. Dendrimers also possess many
unique properties that make them a good nanoparticle platform for antimicrobial drug
delivery. They are highly arranged and regularly branched globular macromolecules, with a
core, layers of branched repeat units emerging from the core and functional end groups on the
outer layer of repeat units [159]. Dendrimer biocides may contain quaternary ammonium salts
as functional end groups displaying greater antimicrobial activity against bacteria than small
drug molecules, due to a high density of active antimicrobials on the dendrimer surfaces [160].
Dendrimers can be made from a wide variety of biocompatible materials, the most frequently
used are polyamidoamine (PAMAM), polyethylene oxide (PEO), polypropylene imine (PPI),
polyethyleneimine (PEI), polyethylene glycol (PEG) etc [161]. PAMAM dendrimers are
dendritic polymers characterized by regular branching and radial symmetry. PAMAM
dendrimers have illustrated useful drug delivery and antimicrobial applications with amino-
terminated dendrimers showing high antibacterial efficacy [162]. It is well known that
PAMAM dendrimers with primary amine surface functional groups may enter the cellular
membrane. Sulfomethoxazole (a sulfonamide derivative poorly soluble and thus presenting
low bioavailability) was administered with PAMAM dendrimers in vitro [163]. Sulfamethox‐
azole (SMZ)-encapsulating PAMAM dendrimers led to sustained release of the drug in vitro
and 4–8 folds increased antibacterial activity against E. coli, compared to free SMZ [163].
7.10. Zeolites
Zeolites are solid hydrated crystalline materials with frame-works comprising silicon,
aluminum and oxygen and featuring nano-channels and cages of regular dimensions [164].
Silica is a neutral regular tetrahedronin in which positive charge of silicon ion is balanced by
oxygen [165]. The capacity of cation exchange depends on the ratio of silica/alumina in the
structure. Generally, zeolits with a low silica/alumina (Si/Al) ratio have higher ion exchange
capacity. According Si/Al ratio, there are several types of natural and synthetic zeolites
including zeolite-β, zeolite A, zeolite X and zeolite Y, which are the most common commercial
adsorbents [165]. Zeolites are minerals with selective pores that can be used to sieve molecules
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having certain dimensions [166]. Several recent studies showed that the potential of zeolites
in medical applications is due to their structural properties and stability in biological envi‐
ronments [167]. Zeolites have also been explored as suitable hosts for the encapsulation of drug
molecules, in search for efficient drug delivery sysytems. Both zeolites and drugs have been
administrated simultaneously to a patient without loss of the individual pharmacological
effect of the drugs [164, 167]. Coating or impregnating zeolite with metallic silver nanoparticles
to prepare zeolite composites can enhance the antibacterial ability of materials, and these
materials can inhibit bacterial growth effectively [168]. It has been reported that silver
embedded zeolite A was found to be antibactrerial against E. coli, Bacillus subtilis and staphy‐
lococcus aureus [165]. Moreover, polymer composites of plasticized poly (vinylchloride) pellets
with silver zeolites demonstrated activity against S. epidermidis and E. coli, while polyurethane
composites with silver zeolites showed antimicrobial action against E. coli and polylactid
acidpolylactide (PLA)/silver zeolite composites also presented activity against S. aureus and
E. coli, with silver being effectively released from the films [169].
7.11. Quantum dots
Quantum dots (QDs) are nanocrystals formed by semiconductor materials, showing attractive
photophysical properties, containing high quantum yield, resistance to photobleaching, and
harmonic photoluminescence, making them potentially powerful tools in a range of biomed‐
ical applications [170, 171]. QDs are typically in the size range between 1 nm and 10 nm,
composed of groups II–VI (e.g., CdSe) or II–V (e.g., InP) elements of the periodic table. QDs
are highly bright, photostable and possess high quantum yield [172]. Due to their very small
size, they possess unique properties and behave in different way than crystals in macro scale
[173]. Water-soluble QDs may be cross-linked to biomolecules such antibodies, oligonucleo‐
tides, or small molecule ligands to render them specific to biological targets [174]. A variety of
techniques have been explored to label cells internally with QDs, using passive uptake,
receptor-mediated internalization, chemical transfection, and mechanical delivery. QDs have
been loaded passively into cells by exploiting the innate capacity of many cell types to uptake
their extracellular space through endocytosis [175, 176]. Krauss group utilized CdSe/ZnS
streptavidin-coated QDs to detect solitary pathogenic E. coli O157:H7 in phosphate buffer
saline solution [177]. Biotinylated anti-E. coli O157:H7 distinguished streptavidin-coated QDs
via famous avidin–biotin binding. Once treated, QD labeled antibody selectively targeted
pathogenic E. coli O157:H7 over common lab strain E. coli DH5α. This assay represented 2
orders of magnitude more sensitivity than using an organic dye with minimal non-specific
binding between the QDs and the bacterial cells [178]. Recently, Luo et al. reported that CDTe
QDs coupled to a rocephin antibiotic complex exhibited antibacterial activity against Escheri‐
chia coli [179]. The mechanism for the antimicrobial activity of QDs is unclear, but it is possible
that QDs can produce singlet O2, a source of free radicals, under irradiation. Heavy metal ion
oxides can also form the QDs core and result in antimicrobial activity [180]. A recent and
excellent review emphasized the application of bioconjugated quantum dots for the detection
of food contaminants such as pathogenic bacterial toxins like botulinum toxin, enterotoxins
produced by Staphylococcus aureus and Escherichia coli [181].
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8. Antibacterial activity of carrier systems for intracellular infection
Treatment of intracellular bacterial infection remains both a medical and economic challenge.
Pathogens thriving or maintaining themselves in cells, or simply taking transient refuge
therein, are indeed shielded from many of the humoral and cellular means of defense. They
also seem more or less protected against many antibiotics [182]. Various infectious diseases
are caused by facultative organisms that are able to survive in phagocytic cells. The intracel‐
lular location of these microorganisms protects them from the host defence systems and from
some antibiotics with poor penetration into phagocytic cells. Intracellular infections are
especially difficult to eradicate because bacteria fight for their survival using several ingenious
mechanisms: inhibition of the phagosome–lysosome fusion, resistance to attack by lysosomal
enzymes, oxygenated compounds and defensins of the host macrophages, escape from the
phagosome into the cytoplasm [183]. Thus, the need for the development of improved
antimicrobial chemotherapeutics and prophylaxis strategies is increasing [4]. In spite of the
availability of a wide variety of in vitro active antibiotics, therapeutic deficiencies are reported,
mainly because of the inability of the drugs to reach the bacteria harboring intracellular
compartments or to perform their activity in the intracellular environments [182, 183].
However, the poor cellular penetration limits these use in the treatment of infections caused
by intracellular pathogens [183]. One strategy utilized to improve the penetration of antibiotics
into phagocytic cells is the use of carrier systems that deliver these drugs directly to the target
cells [185]. Several in vivo and in vitro studies have reported the potential applications of various
carrier systems to enhance the selectivity of antibiotics for phagocytic cells and sustain
therapeutic efficiency in the treatment of intracellular infections [31].
8.1. Infections due to mycobacteria
Tuberculosis, caused by Mycobacterium tuberculosis, is a ordinary lung infection that is even
endemic to specified regions. Its prevalence has increased recently because it is often associated
with AIDS. The Mycobacterium avium complex (MAC) complex is the main cause of hardships
in immunodepressed patients [186]. There are drugs that are efficient against tuberculosis, but
these are used in extended treatment, increasing the risk of side effects [187]. Moreover,
tuberculosis has emerged as an occupational disease in the health care set-up. Although an
effective therapeutic regimen is available, patient non-compliance (because of the need of
taking antitubercular drugs daily or several times a week) results in treatment failure as well
as the emergence of drug resistance [188]. The use of delivery systems facilitates the selective
shuttling of antibiotic to the site of infection and such systems provide slow and prolonged
drug release, which permits administration over longer intervals of time [189]. The encapsu‐
lation of antitubercular drugs in polymeric particles is another strategy to improve the current
therapeutic regimen of tuberculosis. In the last few years several antitubercular drugs-
containing PLGA and PLA microparticles and mainly nanoparticles have been comprehen‐
sively studied [190]. Fawaz et al. encapsulated the synthetic drug ciprofloxacin in
polyisobutylcyanoacrylate (PIBCA) nanoparticles. When testing these nanoparticles against a
M. avium infection in a human macrophage culture, it was found that though nanoparticle
associated ciprofloxacin was more effective than unbound ciprofloxacin, it was much less so
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than anticipated [191]. Rifampicin-loaded polybutylcyanoacrylate nanoparticles have shown
enhanced antibacterial activity both in vitro and in vivo against S. aureus and M. avium due to
an effective delivery of drugs to macrophages [192]. The encapsulation of different antibiotics
in liposomes has shown good antibacterial efficacy in both macrophage cell lines and in animal
models of MAC-due disease [193]. Ciprofloxacin efficiently inhibits the growth of M. avium in
vitro in a murine macrophage-like cell line using negatively charged liposomes and in vivo
using specific stealth liposomes in a mouse model of tuberculosis infection [194]. Similar results
have been obtained using stealth liposomes of isoniazid and rifampicin, which show controlled
release and reduce toxicity in vivo in mice infected with M. tuberculosis [195].
8.2. Brucellosis
Brucellosis is an infectious disease caused by Brucella spp. Four species, Brucella abortus, Brucella
melitensis, Brucella suis and Brucella canis, have been recognized as human pathogens each
associated with a different natural host animal [196]. These small coccobacilli are mainly
localized intracellularly within phagocytic cells making treatment difficult, since most
antibiotics, although highly active in vitro, do not actively pass through cellular membranes
[197]. However in the last two decades many experiments have provided good evidence
criteria for its antibiotic treatment, the most suitable antimicrobial therapy for human brucel‐
losis continues to be a controversial subject [198]. Because of its intracellular location, long
treatments with several antibiotics are required. Relapses are frequent owing to the low
efficacy of many drugs and the lack of patient agreement [199]. Thus, alternative methods such
as drug delivery systems to achieve high intracellular bactericidal activity should be consid‐
ered [198]. Gentamicin, encapsulated in different types of liposomes, has been evaluated
against murine monocytes infected with B. abortus. All such liposomes reduced the number of
bacteria, the most effective being SPLVs (stable plurilamellar vesicles) [200]. Rifampicin-
loaded mannosylated dendrimers have indicated specific pH-dependent delivery of this
antibiotic to rat alveolar macrophages [201]. Recently, gentamicin loaded poly (D, L-lactide-
co-glycolide) (PLGA) have been obtained by the several emulsion solvent evaporation method
for the treatment of brucellosis [202]. Thus, alternative methods such as DDS to achieve high
intracellular bactericidal activity seem promising. The possible use of drug delivery systems
containing aminoglycosides may be one of the most appropriate therapeutic advances in
human brucellosis treatment in the recent years [203].
8.3. Salmonellosis
Salmonellosis is one of the most serious food-borne diseases affecting humans. It may be
considered the most important pandemic zoonosis under natural conditions [204]. Bacteria of
the genus salmonella are facultative intracellular parasites that cause salmonellosis and typhoid
fever. Antibiotics effective against this type of bacteria have limitations owing to the problems
of formulation, low penetration, or the appearance of side effects; these can be solved using
carrier systems [205]. Several studies using antibiotic-loaded nanoparticles have been per‐
formed in order to recognize the suitability and efficacy of these carriers in experimental
models of salmonellosis [204]. In order to recognize whether polyalkycyanoacrylate nanopar‐
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ticles were also effective against non-dividing bacteria, Page-Clisson et al. studied the effec‐
tiveness of these carriers in a model of persistent Salmonella typhimurium infection [206]. They
found that although at early stages of the infection, when bacteria are actively dividing, there
was an antibacterial effect, neither free nor nanoencapsulated ciprofloxacin or ampicillin could
significantly reduce infection in the liver or the spleen at later stages [206]. Liposomal cipro‐
floxacin, administered intravenously and intraperitoneally to mice infected with intracellular
S. typhimurium, has increased habitation time in plasma and the concentration of drug in the
liver, spleen, lungs and kidneys is also increased, while when administered intratracheally its
pulmonary retention is increased. Compared with free ciprofloxacin, it extends survival and
reduces the number of bacteria in the liver and spleen [207]. Therefore, alternative methods
such as DDS which achieve high protective and bactericidal activity should be taken into
account in the future as suitable treatments for Salmonella-induced infections [203].
8.4. Lysteriosis
Lysteria monocytogenes is a facultative intracellular parasite able to cause meningitis and
septicaemia. The encapsulation of ampicillin in liposomes decreases the survival of L. mono‐
cytogenes in mouse peritoneal macrophages to different extents, depending on the composition
of the liposomes [208]. Chitosan-coated plastic films, alone or loaded with antimicrobial agents,
were evaluated for their effect against L. monocytogenes. These chitosan-coated films inhibited
this pathogen growth in a concentration-dependent manner whereas chitosancoated films
impregnated with antibiotics were significantly more effective against L. monocytogenes [209].
Formulation of gentamicin in liposomes containing DOPE (dioleylphosphatidylethanolamine)
and sensitive to pH has been reported to increase the concentration of drug in mouse macro‐
phages infected with L. monocytogenes, increasing its bactericidal activity. This formulation is
more effective against L. monocytogenes than against other bacteria owing to its location in the
cytosol [210]. Furthermore, the efficacy of liposomes and free antibiotic were distinguished in
Listeria-infected mice. Seven days after the treatment, ampicillin-loaded liposomes had
reduced the infection by 3.2 logs in the liver and 2.8 logs in the spleen, while free ampicillin
was ineffective [208]. In another example, ampicillin-encapsulated polyisohexylcyanoacrylate
nanoparticles have been investigated against L. monocytogenes in mouse peritoneal macro‐
phages [211].
9. Specific applications of biodegradable NPs
Attractive features, such as increased dissolution velocity, increased saturation solubility,
improved bioadhesivity, versatility in surface modification and ease of post-production
processing, have widened the applications of nanosuspensions for various routes. One major
problem with the intravenous administration of colloidal particles is their interaction with the
reticulo-endothelial system [212]. The applications of nanosuspensions in parenteral and oral
routes have been very well investigated and applications in pulmonary and ocular delivery
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have been discovered. However, their applications in buccal, nasal and topical delivery are
still awaiting exploration [213].
9.1. Oral delivery
In recent years, significant research has been done using nanoparticles as oral drug delivery
vehicles. Oral delivery of drugs using nanoparticles has been shown to be far superior to the
delivery of free drugs in terms of bioavialability, residence time, and biodistribution [214]. Oral
drug delivery is the choicest route for drug administration because of its non-invasive nature
[215]. The drugs may also be susceptible to gastrointestinal degradation by digestive enzymes.
The advantage of using polymeric nanoparticles is to permit encapsulation of bioactive
molecules and maintain them against enzymatic and hydrolytic degradation [214] The use of
submicron-size particular systems in oral drug delivery, especially peptide drugs, has attracted
considerable pharmaceutical interest [216]. The efficacy or proficiency of the orally adminis‐
tered drug commonly depends on its solubility and absorption through the gastrointestinal
tract. Therefore, a drug candidate that represents poor aqueous solubility and/or decomposi‐
tion-rate limited absorption is believed to possess low and/or highly variable oral bioavaila‐
bility [212]. Despite numerous studies providing evidence that oral delivery of encapsulated
antigens can efficiently elicit immune responses, up to now, less studies report a protection
induced by antigen loaded particles administrated by the oral route against a challenge with
the pathogen [217]. Fattal et al. achieved the protection of mice against S. typhimurium
following oral administration of S. typhimurium phosphorylcholine antigen encapsulated in
PLGA particles [218]. Pinto and Muller (1999) incorporated SLN into spherical pellets and
investigated SLN release for oral administration [219]. Orally administered antibiotics such as
atovaquone and bupravaquone replicate this problem very well. Nanosizing of such drugs
can lead to a dramatic increase in their oral absorption and consequently bioavailability [212].
9.2. Pulmonary delivery
Besides its non-invasive nature, pulmonary drug delivery has many other advantages
compared to alternative drug delivery strategies, containing a large surface area for solute
transport, rapid drug uptake, and improved drug bioavailability [220, 221]. Delivery of
antimicrobial agents to the lung via systemic NP administration is persistent and potentially
harmful upon systemic exposure to the drugs. Alternatively, various NPs exhibiting prefer‐
ential accumulation in the lung and other organs have been tried. It was reported that
intratracheally administered antibiotics loaded NPs were able to penetrate through the
alveolar-capillary barrier into the systemic circulation and accumulate in extrapulmonary
organ containing liver, spleen, bone, and kidney [222]. Micronization of drugs plays an
important role in improving the drug dosage form and therapeutic efficiency today. If a drug
is micronized into microspheres with suitable particle size, it can be addressed directly to the
lung by the mechanical prevention of capillary bed in the lungs [223]. Nanosuspensions may
demonstrate to be an ideal approach for delivering drugs that display poor solubility in
pulmonary secretions [212]. Furthermore, because of the nanoparticulate nature and uniform
size distribution of nanosuspensions, it is very likely that in each aerosol droplet at least one
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drug nanoparticle is contained, leading to even distribution of the drug in the lungs as
compared to the microparticulate form of the drug. In regular suspension aerosols many
droplets are drug free and others are highly filled with the drug, directing to uneven delivery
and circulating of the drug in the lungs. Nanosuspensions could be utilized in all available
types of nebulizer [224]. In a recent study, antitubercular drugs (rifampicin, isoniazid and
pyrazinamide) were incorporated into various formulations of solid lipid particles ranged
from 1.1–2.1 μm and formulations were nebulized to guinea pigs by mouth for direct pulmonar
delivery [212]. Similarly, conditions such as pulmonary aspergillosis can easily be targeted by
using suitable drug candidates, such as amphotericin B, in the form of pulmonary nanosus‐
pensions instead of using stealth liposomes [225].
9.3. Ocular delivery
Nanosuspensions can assay to be a advantage for drugs that show poor solubility in lachrymal
fluids. For delivery of such drugs, approaches such as suspensions and ointments have been
proposed. Although suspensions present advantages such as extended residence time in a cul-
desac (which is desirable for most ocular diseases for effective treatment) and avoidance of the
high tonicity produced by water-soluble drugs, their actual performance depends on the native
solubility of the drug in lachrymal fluids. Thus, the intrinsic decomposition rate of the drug
in lachrymal fluid governs its release and ocular bioavailability [226]. An approach that has
recently been investigated to achieve the desired duration of action of the drug is the formu‐
lation of polymeric nanosuspensions loaded with the drug [212]. Ocular drug administration
via SLN has been reported several times. Ocular drug administration via SLN has been
reported several times [227]. Cavalli et al (2002) evaluated SLN as carriers for ocular delivery
of tobramycin in rabbit eyes. As a result SLN significantly enhanced the drug bioavalability
in the aqueous humor within 6 hours [228]. In addition, poly-cationic polymers may be useful
penetration enhancers for ocular drug delivery [229]. De Campos et al. discovered the potential
of cyclosporin-A loaded nanoparticles for the management of extraocular disorders, i.e.
keratoconjunctivitis sicca or dry eye disease. They reported that the advantages of these
systems in ocular drug delivery contain their ability to contact intimately with the corneal and
conjunctival surface, thereby increasing delivery to external ocular tissues without compro‐
mising inner ocular structures and systemic drug exposure, and to provide these target tissues
with long term drug level [230]. De Salamanaca et al. have reported that chitosan nanoparticles
readily penetrate conjunctival epithelial cells and are well suffered at the ocular surface of
rabbits [231].
9.4. Brain delivery
There is a great interest in the development of drug delivery systems that could allow an
efficient and sitespecific transport of drugs to the target tissues affected by the disease. One of
the most challenging barriers in the body is the blood–brain barrier (BBB) [232]. Endothelial
cells of the BBB limit the solute movement into the brain by regulating transport mechanisms
at the cell surface. These transport mechanisms help to keep the harmful substances out of the
brain in order to maintain homeostasis [233]. Besides the development of simple prodrugs, an
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emerging approach to circumvent the BBB is the use of liposomes, polymeric nanoparticles or
solid lipid nanoparticles, in which the therapeutic drugs can be adsorbed or entrapped [234].
A drug can passively spread through the BBB in a more efficient manner after it is transformed
into a more lipophilic prodrug. The same principle can be applied to brain targeting by
delivering drugs on nanocarriers with enhanced lipophilicity. Fenart et al demonstrated that
when polysaccharide nanoparticles were coated with a lipid bilayer, a 3 to 4-fold improvement
in brain uptake without disruption of the BBB integrity was observed [235]. It has been reported
that poly (butylcyanoacrylate) nanoparticles were able to deliver hexapeptide dalargin,
doxorubicin and other agents into the brain which is significant because of the great difficulty
for drugs to cross the BBB [236]. Recently dendrimers have been evaluated for CNS delivery
of antiretrovira (ARVs) too. Polyamidoamine dendrimers loaded with lamivudine, a nucleo‐
side/nucleotide reverse transcriptase inhibitor (NRTI) commonly utilized in HIV treatment,
were evaluated for their in vitro antiviral activity inMT2 cells infected with HIV-1. When loaded
on dendrimeric nanocarriers, a 21-fold increase in cellular lamivudine uptake and 2.6-fold
reduction in the viral p24 levels were observed when compared to the group treated with free
drug solution [237]. In summary, nanoparticles are a very useful and universal method to
deliver drugs to the brain. Industrial applications of the nanosphere technology would have
several benefits: 1) Nanoparticles deliver drugs to the brain that normally do not cross the
blood-brain barrier. 2) They reduce peripheral side effects of (approved) drugs that cross the
BBB by increasing the relative dose of drugs reaching the brain; 3) Nanoparticles can also be
used as a screening tool. Delivering drug candidates to the brain by nanosphere technology
for initial screening of CNS activity obviates direct CNS injections [238].
10. Conclusion
In many healthcare facilities around the world, bacterial pathogens that express multiple
resistance mechanisms are becoming the norm, complicating treatment and increasing both
human morbidity and financial costs. Until now, no antibiotic therapy has been reported to
eliminate most intracellular bacteria such us Brucella or Mycobaterium too. Furthermore, a
prolonged exposure to combined antibiotics is required to reduce the disease relapses down
to 5-15%. In this sense, drug delivery scientists are searching for the ideal nanovehicle for the
ideal nanodrug delivery system; one that would dramatically reduce drug dosage, improve
in the drug absorption so that the patient can take a smaller dose, and yet have the same benefit,
deliver the drug to the right place in the living system, increase the local concentration of the
drug at the favorite site and limit or eliminate side effects. Compared with other colloidal
carriers, polymeric particles, mainly nanoparticles, have appeared more recently as attractive
carriers for the delivery of drugs to infected cells. Synthetic biodegradable and biocompatible
polymers have been shown to be effective for encapsulating a great variety of antibiotics. In
addition, these polymeric particles powerfully enhance phagocytosis and are suitable for
intracellular delivery of antibacterial agents. With the continuous attempts in this field, there
is no doubt that nanoparticle-based drug delivery systems will continue to improve treatment
to bacterial infections, particularly in life-threatening diseases such as tuberculosis infections.
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Today the application of nanotechnology in drug delivery is widely expected to change the
scenery of pharmaceutical and biotechnology industries for the foreseeable future. Target-
specific drug therapy and methods for early diagnosis of pathologies are the precedency
research areas where nanotechnology would play a prominent role.
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